Korean Market
EXCH
SK Bioscience
★

SK Bioscience Discloses 2026 Corporate Governance Report... Board-Centered Management and Transparency Emphasized, No Shareholder Returns Yet

 
FTC
SK Bioscience
★

SK Bioscience Reports 2025 Operating Loss of KRW 119.1B, SK Chemical Maintains 66.35% Stake – Routine Conglomerate Disclosure

 
MATR
SK Bioscience
★★

Treasury Share Acquisition for Employee RSU Compensation - Daily Purchase Limit 39,125 Shares

 
PERI
SK Bioscience
★

SK Bioscience Q1 2026: CDMO-driven revenue growth, narrowing operating loss, no shareholder returns

 
EXCH
SK Bioscience
★★

RSV Prevention Antibody Technology In-Licensing Agreement (Conditional Milestones of $16.25M)

 
EXCH
SK Bioscience
★★

4Q25 Operating Loss Widens, Net Loss Swings to Deficit

 
EXCH
SK Bioscience
★

Consolidated Revenue Surges 143.5%, Operating Loss Narrows... Net Loss Widens

 
EXCH
SK Bioscience
★

Q4 2025 Earnings Conference Call Announcement

 
EXCH
SK Bioscience
★

SK Bioscience Announces IR for 2026 Q1 Results

 
EXCH
SK Bioscience
★★

Q1 Operating Loss of 44.5 Billion Won, Widening Loss YoY